XML 51 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue from Contracts with Customers (Tables)
12 Months Ended
Dec. 31, 2023
Revenue from Contracts with Customers  
Summary of product revenue provision and allowance

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2020

$

132,775

$

23,779

$

19,055

Provision related to current period sales

378,694

27,229

84,470

Changes in estimate related to prior period sales

1,121

8,763

4

Credits/payments made

(370,211)

(5,154)

(90,303)

Balance as of December 31, 2021

$

142,379

$

54,617

$

13,226

Acquired from BDSI

38,074

18,187

7,575

Provision related to current period sales

497,250

38,250

132,547

Changes in estimate related to prior period sales

(619)

2,505

(592)

Credits/payments made

(520,147)

(40,005)

(130,698)

Balance as of December 31, 2022

$

156,937

$

73,554

$

22,058

Provision related to current period sales

424,013

41,993

149,976

Changes in estimate related to prior period sales

(4,802)

4,268

555

Credits/payments made

(426,322)

(42,310)

(151,672)

Balance as of December 31, 2023

$

149,826

$

77,505

$

20,917

(1)Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s consolidated balance sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s consolidated balance sheets.
Schedule of disaggregation of revenue

Years Ended December 31,

2023

2022

2021

Belbuca

$

182,095

$

126,461

$

Xtampza ER

177,374

    

138,804

    

103,708

Nucynta IR

108,150

112,058

102,222

Nucynta ER

82,653

72,418

70,938

Symproic

16,495

12,267

Other

1,925

Total product revenues, net

$

566,767

$

463,933

$

276,868